Ozempic has been approved to reduce the risk of worsening kidney disease and cardiovascular death in adults with Type 2 ...
Eli Lilly er danske Novo Nordisks største konkurrent på medicinalmarkedet inden for diabetes og overvægt. Novo ...
Novo Nordisk reported strong sales growth for its Wegovy and Ozempic drugs, while its 2025 guidance topped expectations. Shares in Novo, one of Europe's largest listed companies, rallied in the U.S.
In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...
The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...
Lægemiddelstyrelsen i USA, FDA, har tirsdag godkendt Novo Nordisks diabetesmiddel Ozempic til behandling af kronisk ...
Det er USA's føderale fødevare- og lægemiddelmyndighed (FDA), der har godkendt medicinen, som er blevet udviklet og bliver solgt af Novo Nordisk. Dermed kan lægemidlet bruges til at behandle endnu ...
(Reuters) -The U.S. FDA has approved Novo Nordisk (NYSE:NVO)'s Ozempic for reducing the risk of kidney failure and disease progression, as well as death due to heart problems in diabetes patients ...
The Food and Drug Administration approved Novo Nordisk's Ozempic for patients with both chronic kidney disease and diabetes, expanding the use of the wildly popular injection in the U.S. The FDA ...
US FDA Approves Novo Nordisk's Ozempic to Cut Risk of Diabetic Kidney Disease Progression (Reuters) -The U.S. FDA has approved Novo Nordisk's Ozempic for reducing the risk of kidney failure and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback